Click here for slides on this topic


IFG

Abbreviation for impaired fasting glucose. IFG is a level of fasting plasma glucose that is higher than normal but lower than that associated with diabetes. It is defined as being greater than or equal to 100 mg/dL but less than 126 mg/dL. See also Prediabetes.
The following content matched the glossary term: IFG

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

ADA 2016 Type 2 Diabetes Prevention

Top

Recommendations for type 2 diabetes prevention or delay from the 2016 ADA guidelines

Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: The Korean Heart Study.

Top

Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, Park SW, Yun YD, Baek SJ, Mok Y, Jee SH. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women The Korean Heart Study. Diabetes Care. 2012 Sep 21. Epub ahead of print. The relationship between impaired fasting glucose (IFG) and risk of cardiovascular disease (CVD) or ischemic heart disease (IHD) varies widely according to sex and ethnicity. We evaluated the relationship between IFG and CVD or IHD among Korean men and women.

Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.

Top

Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695-704. The Swedish Obese Subjects (SOS) study compared the long-term effects of bariatric surgery with the effects of usual care for type 2 diabetes prevention among 3,429 subjects with obesity.

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

JUPITER Analysis: Do Statin Benefits Outweigh Diabetes Risk?

Top

Exclusive! Expert commentary from Peter Libby, MD, on this analysis of the JUPITER trial. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

Top

Defronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP 4 inhibitor alogliptin combined with pioglitazone, in metformin treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Mar 14. Epub ahead of print. Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control.

1 2 3 4 5 6 7 8 9 Next 

Slide Library Results

Search Results for: IFG Slides Found: 39
ALLHAT: Clinical Outcomes in Antihypertensive Treatments
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Type 2 Diabetes in US Adults: Overview
DECODE: IFG and IGT Are Associated With Increased Mortality Rate
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
ORIGIN: Design
ORIGIN-GRACE: Design
ORIGIN-GRACE: Select Baseline Characteristics
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Values Indicating Prediabetes PPT | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Type 2 Diabetes Prevention ADA Guidelines 2016 | NDEI PPT